Presymptom Health is open to investment discussions to join us on our journey to build a revolutionary portfolio of COVID, sepsis and general acute care tests.
|Investor Profiles||Syndicates, Venture Capitalists|
|Raised to Date||£200k – Ploughshare Innovations. View Press Release|
Sepsis is the immune system’s overreaction to an infection or injury and is associated with life-threatening organ dysfunction. The challenge with treating patients with sepsis is that by the time symptoms become present the patient is already very ill and mortality rates can exceed 50%.
Sepsis is a major public health challenge and associated treatment costs are also considerable.
Presymptom was founded to exploit the intellectual property arising from a 10-year Ministry of Defence clinical discovery programme. This includes a unique presymptomatic 72,000 sample biobank and clinical outcomes database, together with a portfolio of presymptomatic tests for Sepsis that:
The scale of the Sepsis problem is global.
Presymptom has initiated the development of its test portfolio with a seed investment from Ploughshare Innovations. This funding will, over six months, enable the development of our first pre-commercial diagnostic test prototypes and will deliver proof of concept clinical testing in COVID-19 patients.
Presymptom Health is seeking up to £2M over two years to develop its clinical diagnostic test portfolio and reach several key value inflection points. We are targeting first product registration by early 2022 and first commercial revenue within 18 months.